계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Neurovance
company
About
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.
- 1 - 10
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $7M
- Industries
- Biotechnology,Clinical Trials,Health Care,Neuroscience
- Founded date
- Jan 1, 2009
- Number Of Employee
- 1 - 10
- Operating Status
- Close
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD. Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy J. Barberich. It was founded in 2009 and is headquartered in Cambridge, Massachusetts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$13.30M
Neurovance has raised a total of
$13.30M
in funding over 2 rounds. Their latest funding was raised on
Apr 3, 2014 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 3, 2014 | Series A | $6.30M | 1 | — | — | Detail |
| Oct 18, 2012 | Series Unknown | $7M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Neurovance is funded by 1 investors.
H&Q Healthcare Investors
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
